Common Contracts
2 similar null contracts by OncoMed Pharmaceuticals Inc
EX-10.17 39 d344523dex1017.htm FORM OF CHANGE IN CONTROL AND SEVERANCE AGREEMENTCalifornia • May 5th, 2020
[DATE] [NAME] [ADDRESS] Re: Change in Control and Severance Agreement Dear [NAME]: OncoMed Pharmaceuticals, Inc. (the “Company”) considers it essential to the best interests of its stockholders to foster the continuous employment of the Company’s key management personnel. In this regard, the Compensation Committee of the Company’s Board of Directors recognizes that the possibility of an involuntary termination of employment as well as a change in control of the Company may exist and the uncertainty and questions that such concerns may raise among management could result in the departure or distraction of management personnel to the detriment of the Company and its stockholders. In order to induce you to remain in its employ, the Company hereby agrees that after this letter agreement (this “Agreement”) has been fully executed, you shall be entitled to receive the benefits set forth in this Agreement in the event of a change in control of the Company or a termination of your employment w
DATE] [NAME] [ADDRESS] Re: Change in Control and Severance Agreement Dear [NAME]: OncoMed Pharmaceuticals, Inc. (the “Company”) considers it essential to the best interests of its stockholders to foster the continuous employment of the Company’s key...OncoMed Pharmaceuticals Inc • May 11th, 2012
Company; (ii) a merger or consolidation in which the Company is a party; or (iii) the sale, exchange, or transfer of all or substantially all of the assets of the Company (each, a “Transaction”), wherein the stockholders of the Company immediately before the Transaction do not retain immediately after the Transaction, in substantially the same proportions as their ownership of shares of the Company’s voting stock immediately before the Transaction, direct or indirect beneficial ownership of more than fifty percent (50%) of the total combined voting power of the outstanding voting securities of the Company or the successor entity, or, in the case of a Transaction described in (iii), the corporation or other entity to which the assets of the Company were transferred, as the case may be.
